Dr. Matthew Galsky highlights the impact of Imfinzi’s adjuvant approval for patients with muscle-invasive bladder cancer following cystectomy and chemotherapy.
Dr. Matthew Galsky
Advertisement
Galsky serves as a professor of Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute, part of the Mount Sinai Health System, in New York. Galsky is also the director of Genitourinary Medical Oncology, co-director of the Center of Excellence for Bladder Cancer, and associate director for Translational Research, at The Tisch Cancer Institute.
Articles by Dr. Matthew Galsky
"Dr. Rosenzweig’s commitment to helping patients with lung cancer and mesothelioma is truly heroic," several colleagues write.
Matthew Galsky, M.D., professor of Medicine at the Icahn School of Medicine at Mount Sinai, discusses the different stages and curability of bladder cancer.
Advertisement
Latest Updated Articles
Understanding the FDA Imfinzi Combo Approval for Bladder Cancer CarePublished: April 25th 2025 | Updated:
Matthew Galsky Gives an Overview of Bladder CancerPublished: September 30th 2016 | Updated:
Advertisement
Advertisement
Trending on CURE
1
A Survivor's 30-Year Wait for Lymphedema Relief Ends with Hackensack's New Supermicrosurgery Robotic Procedure
2
FDA Grants Orphan Drug Designation to MNV-201 for Myelodysplastic Syndrome
3
Gastrointestinal Stromal Tumor: Comprehensive Patient Guide
4
Jakafi Trial Shows Benefits for Patients with Myelofibrosis and Anemia
5
